The Technological Shift in AYUSH Regulation
Ayurvedic manufacturing in India is moving from paper files to a single digital system. This shift is reshaping how the government licenses, tracks, and verifies every AYUSH product on the market.
The Paradigm Shift: From Paper-Based Licensing to C-DAC's Digital Infrastructure
For decades, the Drugs and Cosmetics Act, 1940 governed the Ayurveda, Siddha, Unani, and Homoeopathy (ASU&H) sector through separate state licensing offices. Each state kept its own paper records.
This gap created real risks. Illicit manufacturers could exploit inconsistent state numbering systems, slip past pharmacovigilance (drug-safety) monitoring, and avoid accountability for adulterated products.
To close these gaps, the Ministry of AYUSH worked with the Central Drugs Standard Control Organization (CDSCO) to launch the e-Aushadhi portal. Built and maintained by the Centre for Development of Advanced Computing (C-DAC), e-Aushadhi is a web-based licensing and supply-chain platform that now anchors AYUSH regulation nationwide.
The portal connects every part of the system in one place:
- State Licensing Authorities (SLAs)
- State drug inspectors
- Analytical testing laboratories
- Pharmaceutical manufacturers
By linking these groups into one secure digital ecosystem, e-Aushadhi digitises the full lifecycle of a traditional medicine, from raw material to finished product.
Why the Government Built e-Aushadhi: Three Core Objectives
The rollout serves three connected goals:
- Stop adulteration and counterfeiting. Remove misbranded and fake traditional medicines from the legitimate retail supply chain.
- Standardise manufacturing quality. Enforce the Ayurvedic Pharmacopoeia of India (API) and Schedule T Good Manufacturing Practices (GMP) across every licensed facility.
- Match global pharma standards. Align Indian AYUSH manufacturing with international compliance benchmarks to make it easier for Indian brands to compete abroad.
The stakes are significant. India's Ayurvedic market is projected to grow from USD 10.6 billion in 2025 to USD 25.8 billion by 2035, a compound annual growth rate of 9.3%. Digital traceability directly supports this growth: it provides manufacturers with a faster, more reliable path to a Certificate of Pharmaceutical Product (WHO-COPP), the credential exporters need to sell AYUSH products internationally.
What is the e-Aushadhi portal?
The e-Aushadhi portal is a mandatory, centralised platform built by C-DAC for the Ministry of AYUSH. It manages licensing and supply-chain oversight for Ayurvedic, Siddha, Unani, and Homoeopathy manufacturers. The portal digitises manufacturing approvals, enforces regulatory compliance, and provides end-to-end cryptographic traceability, closing the door on counterfeit and adulterated products nationwide.
In short, e-Aushadhi turns a fragmented, paper-based licensing system into one verifiable digital record, giving Indian AYUSH manufacturers the traceability they need to build trust at home and open new markets abroad.
e-Aushadhi portal: the digital backbone of AYUSH manufacturing licenses
Form 24D vs Form 25E: what separates them
| Aspect | Form 24D route | Form 25E route |
|---|---|---|
| Arrangement | In-house manufacturing facility | Loan license: uses a third-party manufacturer's premises, equipment and technical staff |
| Application form | Form 24D | Form 25E |
| Resulting license | Form 25D | Form 25E |
| Ownership of infrastructure | Applicant owns the facility | Applicant does not own the infrastructure |
| Validity | Perpetual, subject to GMP maintenance and annual self-compliance declarations | Perpetual, subject to the same conditions |
The perpetual-validity provision is a recent statutory shift. It removes the historical requirement for periodic manual renewals, and licensees keep their status active by maintaining GMP certification and filing annual self-compliance declarations through the portal itself.
How the e-Aushadhi workflow verifies a license application
The diagram above traces the six-stage path: a manufacturer submits site blueprints and staff credentials, the State Licensing Authority (SLA) checks those documents, the manufacturer links to an approved public testing laboratory, the SLA conducts a physical site inspection and GMP audit, the system issues the perpetual Form 25D or Form 25E license, and the entity enters the national track-and-trace ledger.
Premises requirements: area, layout and Schedule T rules
- Minimum operational area: 1,200 square feet for a single product category, on land zoned for industrial use
- Digitally verified site layouts and blueprints required at application stage
- Schedule T mandates independent space for four functions: raw material receipt, the manufacturing process area, the quality control section and finished goods storage
- Rasaushadhi (herbo-mineral formulations) manufacturers need a dedicated 150 square foot raw material store
- A furnace or Bhatti section (used for calcining heavy metals such as arsenic or mercury) needs a tin roof, proper ventilation and a specialised exhaust system to manage toxic fumes
Staff credentials: the portal cross-checks
- At least 2 registered medical practitioners holding a BAMS (Bachelor of Ayurvedic Medicine and Surgery) or BUMS (Bachelor of Unani Medicine and Surgery) degree
- At least 2 registered pharmacists
- All credentials verified digitally and in real time before the application proceeds
How public testing labs get linked to a manufacturer's dossier
An external public testing laboratory registers independently on the portal, submits its accreditation (commonly ISO 17025 or NABL), and receives SLA approval. Only then can the manufacturer digitally link that lab to their Form 24D or Form 25E dossier. This chain keeps every Certificate of Analysis (COA) tied to a verified, accountable lab, closing the door on forged testing data entering the supply chain.
The 2026 Legacy Module rollout: key dates
| Date | Event |
|---|---|
| April 16, 2026 | All users, including holders of accounts on older portal versions, complete a fresh, cryptographically secure registration |
| April 28, 2026 | C-DAC activates the Legacy Module for digitising historical approval records |
| May 30, 2026 | The e-Aushadhi portal becomes the sole legal channel for AYUSH manufacturing licensing nationwide; offline approvals end permanently |
Every existing Form 25D or Form 25E holder had to upload their previously approved manual records into the Legacy Module: polyherbal formulations, historical GMP compliance certificates and past Form 48 approvals. SLAs then verified this legacy data, and that verification became a hard gate: a manufacturer needed SLA sign-off on legacy records before applying for new product approvals, requesting a WHO-COPP (Certificate of Pharmaceutical Product) for export, or generating new digital batch records.
The compliance load e-Aushadhi is built to ease
Industry audits point to steep numbers for small and mid-size AYUSH manufacturers: a typical MSME carries over 1,450 compliance obligations a year, spread across 59 types of inspectors, at a yearly cost between Rs 13 lakh and Rs 17 lakh. Among surveyed firms, 92% reported production delays tied to pharmacopeial monograph revisions, and 72% of firms needing GMP or GLP upgrades put the capital cost above Rs 2 crore. The portal functions as a Digital Public Infrastructure (DPI) intervention meant to centralise this burden, even though the initial migration phase itself demanded heavy lifting from manufacturers.
Ayush Drugs (Eleventh Amendment) Rules, 2026: S.P.C. Codes, QR Labelling, Microbiologist Rules & Shelf-Life Compliance
In July 2026, the Central Government notified the Ayush Drugs (Eleventh Amendment) Rules, 2026, via Gazette Notification G.S.R. 657(E). The amendment introduces a mandatory six-part Specific Product Code (S.P.C.) for every AYUSH formulation, permits QR-code and GTIN-based digital labelling under Rule 161, requires a qualified microbiologist at every manufacturing site under Rule 160B, and sets strict shelf-life limits under Rule 161B for products approved through accelerated stability studies.
Key takeaways:
- Every AYUSH product now needs a standardised six-component S.P.C. that doubles as its manufacturing license number
- Existing product codes must be reissued in the new S.P.C. format by July 24, 2028
- Manufacturers can now display full ingredient lists via QR code, GTIN, or barcode instead of squeezing them onto physical labels
- A qualified microbiologist must be present at every ASU manufacturing site
- Products approved on accelerated stability data get a maximum 1–2 year provisional shelf life and must follow up with real-time stability data
What Is the AYUSH Specific Product Code (S.P.C.) Under Rule 158B?
The Specific Product Code (S.P.C.) is a standardised, six-part alphanumeric identifier introduced by sub-rule (VII) inserted into Rule 158B of the Ayush Drugs (Eleventh Amendment) Rules, 2026. It functions as a cryptographic identifier that permanently binds every physical AYUSH product moving through the supply chain to its master digital dossier inside the e-Aushadhi database, ensuring absolute uniqueness across millions of distinct production batches.
The 6-Component Structure of the S.P.C. Code
| Code Component | Regulatory Designation | Mechanical Function in Traceability |
|---|---|---|
| State / UT Code | Central Government Specified | Identifies the geographic origin of the product and the jurisdiction of the approving State Licensing Authority (SLA) |
| License Type | "D" or "E" | Distinguishes an in-house manufacturing license (D) from a third-party loan license (E) |
| License Serial Number | Numeric Assignment | Provides the specific, unique serial number of the license issued by the SLA |
| System of Medicine | Classical or "PP" | Classifies the formulation as a classical text-based medicine or a Patent and Proprietary (PP) blend |
| Product Serial Number | Numeric Assignment | Uniquely identifies the specific SKU within the manufacturer's approved portfolio |
| Year of Approval | YYYY | Establishes the chronological vintage of the product's regulatory authorisation |
Why the S.P.C. Also Functions as the Manufacturing License Number
The Eleventh Amendment's core legal mechanism is that it conflates the product identifier with the manufacturing authorisation itself. The State/UT code, license type, and license serial number embedded in the S.P.C. legally constitute the manufacturing license number, meaning generating or printing an S.P.C. is itself a declaration of holding a valid, SLA-verified Form 25D or 25E license. Fabricating these codes is therefore a direct violation of licensing law, subject to immediate prosecution.
"State/Union Territory code/ D or E (License or Loan license)/serial number of license in the product code shall be treated as manufacturing license number." — Gazette Notification G.S.R. 657(E)
Two-Year Transition Window: July 24, 2028 Deadline
The legislation provides a rigid two-year transitional window so the existing supply chain isn't disrupted overnight. Every existing product code across the Indian market must be systematically recalled and reissued to match the uniform S.P.C. pattern by July 24, 2028. Physical labels must reflect the new identifier using a specific mandatory phrase:
"The specific product code of the drug being preceded by the words 'specific product code or S.P.C.', which shall be printed or written within two years of the commencement of the Drugs (Eleventh Amendment) Rules, 2026." - Gazette Notification G.S.R. 657(E)
ADMA's Objection: Are Hydroalcoholic Extracts Really "Ayurvedic Drugs"?
Rule 158B's implementation has generated significant industry friction, particularly from the Ayurvedic Drug Manufacturers' Association (ADMA). ADMA has raised biochemical and philosophical objections to classifying all herbal extracts - specifically hydroalcoholic extracts - as Ayurvedic drugs under the new S.P.C. framework. Classical Ayurveda determines therapeutic value through rasa, guna, veerya, vipak, and prabhav (RGVV&P), using crude powders, decoctions, or aqueous extracts. ADMA argues hydroalcoholic extraction represents a fundamentally different chemistry that deviates from classical texts, and that products relying on modern solvent extraction should sit outside the strict domain of traditional Ayurveda rather than being granted a blanket S.P.C. under Patent and Proprietary (PP) classification.
Rule 161: QR Code and Digital Labelling Rules for AYUSH Packaging
Traditional polyherbal formulations are intrinsically complex - involving dozens of active botanical ingredients, intricate mineral excipients (Bhasmas), specific vehicles of administration (Anupana), and detailed contraindications. Standard packaging's spatial limits have historically forced manufacturers into microscopic, near-illegible ingredient lists, or reliance on separate paper package inserts that consumers easily lose or discard.
The Eleventh Amendment resolves this by amending Rule 161 to permit dynamic digital labelling. Under the newly inserted sub-rule 161(3A), the Ministry of AYUSH formally recognises the legal validity of digital markers as a labelling substitute:
"(3A) All the label information may also be displayed through QR code or..." - Gazette Notification G.S.R. 657(E)
When the full ingredient and excipient list is too extensive for the physical label, manufacturers can now legally display it via:
- Quick Response (QR) Code
- Global Trade Item Number (GTIN)
- Standard barcode
This resolves the packaging space constraint while creating a direct, scannable link between the consumer's smartphone and the e-Aushadhi track-and-trace cloud.
Rule 160B: Mandatory Microbiologist Qualifications at AYUSH Manufacturing Units
The 2026 amendments expanded Rule 160B - which governs the qualifications of technical personnel supervising ASU manufacturing operations - to mandate the continuous presence of a qualified microbiologist at the manufacturing site.
A microbiologist qualifies under Rule 160B if they hold:
- A bachelor's degree in microbiology plus at least 6 months of verified quality control experience, or
- A postgraduate degree in microbiology from a recognised university
This addresses a core risk in ASU manufacturing: because formulations rely heavily on raw, earth-derived botanical materials, they're highly susceptible to microbial contamination, heavy fungal loads, and toxic aflatoxin proliferation if improperly stored or processed. Mandatory microbiological oversight ensures continuous adherence to the microbial limits defined in the Ayurvedic Pharmacopoeia of India (API).
Rule 161B: Shelf-Life Rules for Accelerated Stability Studies
Rule 161B governs how a drug's shelf-life and expiration date are determined, mandating compliance with the stability study protocols in the API, Part I, Volume VIII - modernising the historical practice of estimating shelf-life from classical textual references.
Accelerated stability studies subject a drug to extreme temperature and humidity (typically 40°C ± 2°C / 75% RH ± 5% RH) to artificially speed up chemical degradation, allowing faster market approval. In exchange, the regulator caps the shelf-life that can be granted:
| Accelerated Study Duration | Maximum Shelf-Life Granted |
|---|---|
| 3 months | 1 year |
| 6 months | 2 years |
The catch: to keep market authorisation and S.P.C. status, the licensee must conduct and submit a full real-time stability study report (under standard atmospheric conditions) to the SLA within one year following the expiry of the provisional shelf-life granted on accelerated data. Failing to produce this real-time validation triggers immediate regulatory action and product recall.
Related FAQs
What does S.P.C. stand for in AYUSH regulations?
S.P.C. stands for Specific Product Code - a mandatory six-part alphanumeric identifier assigned to every AYUSH formulation under Rule 158B of the Ayush Drugs (Eleventh Amendment) Rules, 2026.
Is the S.P.C. the same as the manufacturing license number?
Yes. The State/UT code, license type, and license serial number embedded within the S.P.C. legally constitute the manufacturing license number under G.S.R. 657(E).
By when must manufacturers switch to the new S.P.C. format?
All existing product codes must be reissued in the new S.P.C. format by July 24, 2028, under the two-year transitional window.
Can AYUSH manufacturers show ingredient lists only through a QR code?
Yes. Under Rule 161(3A), manufacturers can display the full label information - including extensive ingredient and excipient lists - through a QR code, GTIN, or standard barcode when physical label space is insufficient.
What qualifications does a microbiologist need under Rule 160B?
Either a bachelor's degree in microbiology with at least 6 months of verified quality control experience, or a postgraduate degree in microbiology from a recognised university.
How much shelf-life can accelerated stability studies grant?
A maximum of 1 year based on a 3-month accelerated study, or a maximum of 2 years based on a 6-month accelerated study - both provisional, pending real-time stability data.
Cross-Sector Synergy: Connecting AYUSH Traceability to Allopathic Schedule H2
The digital overhaul of India's AYUSH sector through e-Aushadhi is not happening in isolation - it runs parallel to the national QR code traceability mandate for allopathic drugs under Schedule H2 of the Drugs Rules, 1945. As Indian consumers get used to scanning QR codes on vaccines, antibiotics, and cancer drugs to verify authenticity, that same expectation of digital transparency is now extending to traditional Ayurvedic medicines, and the S.P.C. and Rule 161 QR provisions ensure AYUSH products meet an equivalent standard.
Key takeaways:
- Schedule H2 traceability began in November 2022, covering the top 300 allopathic brands
- A June 22, 2026 notification - G.S.R. 506(E), the Drugs (Seventh Amendment) Rules, 2026 - pulled all vaccines, all antimicrobials, all narcotic and psychotropic drugs, and all anticancer drugs into Schedule H2
- The Schedule H2 QR code must carry nine data elements: unique product ID code, generic name, brand name, manufacturer name and address, batch number, manufacture date, expiry date, manufacturing licence number, and excipient details
- Compliance takes effect July 1, 2027 for vaccines, anticancer drugs, and NDPS narcotics/psychotropics, with antimicrobials given until July 1, 2028
- Rising consumer familiarity with allopathic QR scanning is pushing the same transparency expectation onto Ayurvedic and herbal products
- The AYUSH S.P.C. (Rule 158B) and QR labelling allowance (Rule 161) were designed to keep pace with this national standard
What Is Schedule H2 Under the Drugs Rules, 1945?
Schedule H2 is the framework governing QR code and barcode-based traceability for allopathic pharmaceuticals in India, spearheaded by the Ministry of Health and Family Welfare. In November 2022, the Central Government took the foundational step by notifying G.S.R. 823(E), formally inserting Schedule H2 into the Drugs Rules, 1945. This original framework mandated verifiable QR codes or barcodes on the primary packaging of the top 300 allopathic pharmaceutical brands circulating in the domestic market, as a direct defence against counterfeiting.
The June 2026 Expansion: G.S.R. 506(E) and the Drugs (Seventh Amendment) Rules, 2026
In June 2026, the Health Ministry executed a massive expansion of the Schedule H2 framework. The expansion was formalised through the Drugs (Seventh Amendment) Rules, 2026, notified via G.S.R. 506(E) dated June 22, 2026, following public consultation on draft rules published in October 2025. The amended provisions dictate that all vaccines, critical antimicrobials, anti-cancer medications, and narcotic and psychotropic drugs covered under the NDPS Act, 1985 must now bear a serialised QR code on their packaging.
What the Schedule H2 QR code must display when scanned:
| # | Data Element |
|---|---|
| 1 | Unique product identification code |
| 2 | Proper and generic name of the drug |
| 3 | Brand name |
| 4 | Name and address of the manufacturer |
| 5 | Batch number |
| 6 | Date of manufacture |
| 7 | Date of expiry |
| 8 | Manufacturing licence number |
| 9 | Details of excipients |
These nine elements are the mandated fields for every Schedule H2 QR code under the June 2026 amendment.
Compliance timeline:
| Drug Category | Compliance Deadline |
|---|---|
| Vaccines | July 1, 2027 |
| Anticancer drugs | July 1, 2027 |
| NDPS narcotic & psychotropic drugs | July 1, 2027 |
| Antimicrobials | July 1, 2028 |
Antimicrobials were given the extended 2028 deadline, roughly a year longer than the other three categories.
Why Allopathic QR Standards Are Reshaping Consumer Expectations for AYUSH Products
This macroeconomic shift in allopathic pharmaceutical regulation exerts a profound, unavoidable influence on consumer expectations for traditional AYUSH medicines. As the Indian populace becomes rapidly conditioned to scanning critical allopathic medications - such as broad-spectrum antibiotics and oncology drugs - with their smartphones to verify authenticity, manufacturing origins, and exact shelf-life parameters, their baseline expectation for pharmaceutical transparency fundamentally alters. Consumers inevitably demand the same level of cryptographic transparency and digital accountability from their traditional herbal supplements and over-the-counter Ayurvedic remedies.
How AYUSH S.P.C. and Schedule H2 Align: One National Traceability Standard
The synchronous implementation of the S.P.C. pattern under Rule 158B and the digital QR code labelling allowances under Rule 161 ensures the traditional medicine sector does not suffer a technological deficit relative to allopathic drugs. By aligning AYUSH traceability protocols directly with the established Schedule H2 framework, the government guarantees an interoperable national standard — the data fields embedded within the S.P.C. and the digital label mirror the same category of critical data elements demanded under Schedule H2. Ayurvedic medicines are now subjected to the same rigorous, digitally verifiable supply chain standards as modern allopathic formulations, elevating the entire AYUSH sector's global credibility and signalling to international regulators that Indian traditional medicines are tracked, traced, and verified with the same cryptographic certainty as modern pharmaceuticals.
FAQs
What is Schedule H2 under the Drugs Rules, 1945?
Schedule H2 is a framework requiring specified allopathic drug formulations to carry a QR code or barcode on their packaging for authentication and traceability, first introduced via G.S.R. 823(E) in November 2022 for the top 300 pharmaceutical brands.
What drugs were added to Schedule H2 in 2026?
Vaccines, antimicrobials, anti-cancer medications, and narcotic and psychotropic drugs under the NDPS Act, 1985 were added to Schedule H2 through the Drugs (Seventh Amendment) Rules, 2026, notified via G.S.R. 506(E) on June 22, 2026.
What information does a Schedule H2 QR code contain?
Nine data elements: unique product ID code, generic name, brand name, manufacturer's name and address, batch number, manufacture date, expiry date, manufacturing licence number, and excipient details.
When do the expanded Schedule H2 rules take effect?
July 1, 2027 for vaccines, anticancer drugs, and NDPS narcotics/psychotropics; July 1, 2028 for antimicrobials.
How does AYUSH's S.P.C. system relate to Schedule H2?
Both systems serve the same national goal - supply chain transparency and counterfeit prevention - using QR-scannable digital identifiers that mirror each other's core data fields, ensuring AYUSH and allopathic products meet an equivalent traceability standard.
Consumer Verification Mechanics: The Smartphone User Journey
The final goal of the e-Aushadhi portal, the S.P.C. code, and the newer regulatory rules is simple: build a closed supply chain that protects the patient the moment they buy or take a medicine. A single QR code scan turns any patient, pharmacist, or drug inspector into an active check-point in national drug safety.
This matters because the risk is real. Roughly 1 in 10 medicines sold in low- and middle-income countries fail quality testing and turn out to be substandard or falsified. Verification tools like this QR system exist to close that gap at the exact point where a patient could be harmed.
Technological Execution: URI/GTIN Decoding, SSL API Calls, and C-DAC Server Queries
Verification relies on constant, real-time communication between the printed code on the bottle and the backend systems that store its record: the Drugs and Vaccine Distribution Management System (DVDMS) and e-Aushadhi.
Here's what happens during a single scan:
- Scan. A consumer, a pharmacist at a primary health centre, or a state drug inspector scans the packaging's QR code using a smartphone camera or a dedicated regulatory app.
- Decode. The scanner reads the embedded Uniform Resource Identifier (URI) or GTIN matrix inside the QR code.
- Secure request. The decode triggers an Application Programming Interface (API) call, sent over an encrypted Secure Sockets Layer (SSL) connection.
- Server check. The request reaches C-DAC's central servers, which host both the e-Aushadhi and DVDMS databases.
- Match against records. The system checks the code against its master ledger of approved Form 25D/25E licenses and batch production records.
- Instant response. Within milliseconds, the API sends a standardised data payload back to the user's screen.
The 8 Mandatory Data Points Revealed Upon Scanning
To protect patient safety and guarantee accountability, every valid scan must legally display eight specific data points. These mirror the same transparency rules already used for allopathic medicines under the Schedule H2 standard.
| Displayed Data Point | Clinical & Regulatory Significance |
|---|---|
| Unique Product ID (S.P.C.) | Confirms the product is a legally registered Classical or Patent/Proprietary drug, and not an unregistered formulation. |
| Proper & Generic Name | Identifies the core botanical or mineral composition, protecting against misbranding or substitution with a weaker product. |
| Brand Name | Links the commercial product name directly to its registered S.P.C. file. |
| Manufacturer Name & Address | Provides geographic traceability, confirming the product came from an inspected, GMP-compliant facility. |
| Batch / Lot Number | Supports fast, targeted recalls nationwide within minutes if an adverse drug reaction (ADR) or failed quality test is reported. |
| Mfg & Expiry Date | Confirms the product is still within its tested shelf life, based on stability studies required under Rule 161B. |
| Mfg License Number | Confirms the manufacturer holds a valid, permanently active Form 25D or Form 25E license, verified by the State Licensing Authority. |
| Full Excipient/Ingredient List | Lists every active botanical, calcined mineral (Bhasma), and approved binder or preservative, giving patients the allergy information a small physical label cannot fit. |
The European Union has required a two-dimensional barcode and an anti-tampering seal on prescription medicine packaging since February 2019, and the United States runs a comparable track-and-trace system under the Drug Supply Chain Security Act. e-Aushadhi brings Indian AYUSH products in line with that same global standard.
Preventing Counterfeits via DVDMS Multi-Tiered Node-to-Node Verification
Scanning at the point of sale catches problems late. The stronger safeguard happens earlier: the DVDMS tracks every product movement through the supply chain and flags anything unusual before it ever reaches a patient.
Digital Handshake Protocols: Manufacturer → Warehouse → Retailer
Every step of the supply chain confirms the product's identity before passing it forward:
- The licensed Form 25D manufacturer generates serialised QR codes based on their approved S.P.C. and logs batch volume and serial data into e-Aushadhi before the product leaves the factory.
- The product moves through District Drug Warehouses (DDW), wholesale distributors, and finally Primary Health Centres (PHC) or retail pharmacies.
- Each of these points must scan the product on both receipt and dispatch.
Autonomous Anomaly Detection: Preventing Code Duplication and Unregistered Batches
If someone tries to introduce counterfeit medicine using cloned or copied QR codes, the DVDMS system catches it through location and timing checks.
For example: if a specific S.P.C. serial number is scanned at a warehouse in Maharashtra, but the database already shows that same code was scanned and dispensed to a patient in Gujarat three days earlier, the system flags it as a duplicate immediately. The same happens if a batch of codes shows up with no matching origin log from a registered Form 25D manufacturer. The system treats these as illegitimate on sight.
Once flagged, the system responds automatically:
- Blocks the transaction
- Freezes the batch's digital movement
- Alerts the State Licensing Authority and regional drug inspectorate for a physical follow-up
If a counterfeit product somehow reaches a retail shelf, the next consumer scan will trigger a clear warning on-screen, such as "Product Not Found," "Invalid Batch," or "Counterfeit Warning," stopping the sale before the patient takes the medicine.
Together, these checks turn a single QR code into a full safety net: instant proof of authenticity for the patient, and an early warning system for regulators.
Ayurvedic Quality Control Standards: Heavy Metal Limits, Lab Testing and e-Aushadhi Traceability Explained
Ayurvedic medicines earn public trust when their safety is proven through documented evidence rather than assumption. That proof rests on the Ayurvedic Pharmacopoeia of India (API), the legal benchmark that sets exact heavy metal limits for every formulation, and on a chain of instrumental lab testing and digital traceability that carries a single batch from the manufacturing floor to a QR code a consumer can scan.
1. Why the Ayurvedic Pharmacopoeia of India Is the Legal Benchmark for Safety
The therapeutic efficacy and fundamental safety of traditional Ayurvedic medicines, particularly Rasaushadhi (herbo-mineral preparations) and Bhasmas (calcined metals, minerals, and gems), depend entirely on the flawless execution of the ancient purification process (Shodhana) and the intense incineration process (Marana). When these complex processes are executed with precision, toxic metals are converted into safe, biologically compatible organo-metallic complexes. When execution falls short, the metals remain in a free state, retaining extreme systemic toxicity.
Regulatory context: Modern regulation formalises this centuries-old safeguard through Schedule T, the Good Manufacturing Practice (GMP) framework for Ayurvedic, Siddha, and Unani drugs under Rule 157 of the Drugs and Cosmetics Rules, 1945. Schedule T includes supplementary guidelines written specifically for Rasaushadhi and Kushtajat, covering Bhasmas, Sindura, Pishti, Kajjali, Khalviya Ras, Kupipakwa, Rasayan, Parpati, Potali Rasa, and metallic Satwa preparations, so that classical processing methods carry forward into a validated, auditable manufacturing environment.
The evidence: The World Health Organization applies broadly similar thresholds for lead, mercury, and arsenic in herbal medicines internationally, while several export markets, including the EU and US, hold botanical products to tighter limits for lead, cadmium, and mercury. Placing the API alongside these benchmarks shows Indian Ayurvedic regulation sits within an established global framework rather than outside it, even where individual thresholds vary by market.
2. API's Permissible Heavy Metal Limits, Explained Metal by Metal
To manage the toxicological risks tied to environmental contamination, soil bioaccumulation, or incomplete Bhasma formulation, the API enforces rigid, legally binding thresholds for four heavy metals, measured in parts per million (ppm).
| Heavy Metal | Symbol | API Max Permissible Limit | Primary Toxicological Risk Profile |
|---|---|---|---|
| Lead | Pb | 10.0 ppm | Neurotoxicity, NMDAR inhibition, renal impairment, anaemia, cognitive deficits, developmental delays in children |
| Arsenic | As | 3.0 ppm | Hepatotoxicity, glutathione reductase inhibition, cardiovascular disease, systemic carcinogenesis |
| Mercury | Hg | 1.0 ppm | CNS degradation, protein misfolding, nephrotoxicity, severe motor deficits |
| Cadmium | Cd | 0.3 ppm | Osteotoxicity (bone demineralisation via osteoclast stimulation), irreversible renal tubular dysfunction, acute respiratory distress |
The mechanisms behind each limit:
- Lead (10.0 ppm): Lead is a highly toxic, non-essential metal that crosses cell membranes easily. It non-competitively inhibits the N-methyl-d-aspartate receptor (NMDAR) in the hippocampus, interfering with learning, memory, and cognitive function in ways that become irreversible over time. It also displaces essential calcium and magnesium ions in cellular processes, blocks key enzymatic steps in heme synthesis (driving anaemia), and places sustained stress on kidney function.
- Arsenic (3.0 ppm): Inorganic arsenic acts as a potent protoplasmic poison, binding with high affinity to the sulfhydryl groups of cellular enzymes. It inhibits the glutathione reductase enzyme directly, limiting the body's capacity to clear reactive oxygen species and driving significant oxidative stress. Chronic exposure is linked to acute hepatotoxicity, cardiovascular disease, peripheral neuropathy, hyperpigmentation (including Mees' lines on the nails), and systemic carcinogenesis.
- Mercury (1.0 ppm): Methylmercury is highly lipophilic, which lets it cross the blood-brain barrier readily. It settles into the lipid-dense tissues of the central nervous system, disrupting enzymatic pathways and interfering with protein folding. The result is central nervous system degradation marked by motor deficits, tremors, and concurrent kidney stress.
- Cadmium (0.3 ppm): Cadmium displaces essential zinc from zinc-finger metalloproteins, deactivating the enzymes that depend on them. It inhibits the 1-alpha hydroxylase enzyme in the kidneys, reducing active vitamin D3 production, and it stimulates osteoclast activity while suppressing osteoblast conversion, leading to bone demineralisation and fracture risk. It also triggers a Fanconi-like syndrome in the proximal tubule, producing lasting renal tubular dysfunction.
Why the limits differ so much between metals: Cadmium's limit is more than 30 times stricter than lead's, which reflects how much smaller a cadmium dose needs to be before its zinc-displacement and kidney effects become measurable, compared with the higher body burden lead can reach before crossing the same toxicological threshold.
The evidence: A 2022 assessment of herbal raw materials traded in India tested 183 samples across 74 different herbal raw materials and found cadmium was the most frequent point of failure against API limits (5.46% of samples), ahead of mercury (3.82%), lead (1.09%), and arsenic (0.55%). That pattern lines up with cadmium's markedly tighter threshold: even modest environmental contamination is more likely to push a sample over its 0.3 ppm ceiling than over the far higher limits set for the other three metals.
3. The Four Gold-Standard Laboratory Methods Behind Every Compliance Report
Confirming these limits requires more than the organoleptic evaluation (taste, touch, smell) that classical Ayurveda has historically relied on. Modern AYUSH quality control calls for validated instrumental methodologies, carried out by third-party, NABL-accredited laboratories registered on the e-Aushadhi portal, to generate the data needed for batch release.
ICP-MS (Inductively Coupled Plasma Mass Spectrometry): Ultra-Trace Testing for Nano-Crystalline Bhasmas
ICP-MS detects trace heavy metals and isotopes at extraordinarily low concentrations, down to parts per trillion. The sample, typically prepared through closed-vessel microwave acid digestion, passes through an inductively coupled argon plasma burning at thermal extremes approaching 10,000 Kelvin. This energy ionises the atoms, which are then separated in a mass spectrometer by their mass-to-charge ratio. Its wide dynamic range and rapid multi-element detection make ICP-MS the gold standard for characterising the exact elemental composition of nano-crystalline Bhasmas, confirming that a metal has been properly calcined rather than left in a toxic free state.
AAS (Atomic Absorption Spectroscopy): Routine Flame and Graphite Furnace Metal Testing
AAS relies on the quantum principle that free atoms in a ground state absorb light at a specific, characteristic wavelength. The sample is vaporised and atomised using a high-temperature flame or a graphite furnace, and a light beam of the correct wavelength passes through the resulting atomic vapour. The amount of light absorbed is directly proportional to the element's concentration. AAS is less sensitive than ICP-MS at ultra-trace levels, but it remains a foundational, cost-effective, API-mandated method for routine heavy metal limit testing across standard polyherbal AYUSH formulations.
HPTLC (High-Performance Thin-Layer Chromatography): Phytochemical Fingerprinting and Species Authentication
HPTLC is a highly automated, quantitative evolution of traditional thin-layer chromatography. The sample is applied as a precise, microscopic band onto a silica gel plate, which sits in a developing chamber while a mobile phase solvent travels up the plate through capillary action, separating the botanical mixture into distinct chemical bands. Digital densitometry and multi-wavelength UV/fluorescence imaging then read the plate. HPTLC produces a visual phytochemical "fingerprint" of a polyherbal formulation, making it the gold standard for confirming that the correct plant species was used, such as distinguishing the therapeutic Sida cordifolia from ineffective biological substitutes, while verifying that the plant's chemical matrix remains intact from lot to lot.
LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry): Molecular Fragment Analysis and Adulterant Screening
LC-MS/MS pairs the separation power of liquid chromatography with the specificity of tandem mass spectrometry. Molecules in the sample are separated in a liquid phase, ionised, and passed through two successive mass spectrometers: the first isolates a precursor ion, which is fragmented through collision-induced dissociation, and the second analyses the resulting product ions to map the molecule's unique structural fingerprint. This makes LC-MS/MS the tool of choice for detecting trace pesticide residues, mycotoxins such as aflatoxin B1, and synthetic pharmaceutical adulterants hidden within herbal matrices, since its selectivity is what allows it to identify molecularly complex, unlisted synthetic drugs that counterfeiters attempt to mask inside traditional formulations.
4. From Lab Report to QR Code: How e-Aushadhi Closes the Traceability Loop
Under the modernised regulatory framework, this digital COA is linked directly to the specific batch number and uploaded to the e-Aushadhi portal by the accredited laboratory. Only once the analytical data computationally confirms that the batch meets API limits for heavy metals and botanical identity is the manufacturer authorised to generate a batch-specific QR code (referred to in industry documentation as the S.P.C. code) for that lot.
Regulatory context: The Ministry of AYUSH launched the e-Aushadhi portal in February 2019 as a single-window system for online licensing of Ayurveda, Siddha, Unani, and Homoeopathy drugs. Its name stands for the Ayurveda, Unani, Siddha and Homoeopathy Automated Drug Help Initiative, and it was built to give manufacturers, drug-testing labs, and regulators real-time visibility into licensed products, along with information on cancelled or spurious drugs. The system has continued to expand: as of 2026, mandatory compliance for license-related processing has moved onto the portal, with fresh licence applications and a legacy data-entry module for existing license holders opened from 28 April 2026.
From crackdown to consequence: why the adulteration crisis drove this regulatory overhaul
The mandatory e-Aushadhi onboarding, the Rule 160B requirement for qualified microbiologists, the cryptographic Rule 158B S.P.C. tracking system, and the alignment with Schedule H2 form more than an administrative upgrade. Together they answer a genuine public health emergency: the widespread adulteration of traditional medicines by an unorganized, unlicensed sector that has exploited the deep consumer trust Ayurveda carries as a natural, time-tested system of healing.
The shadow economy behind "puriyas"
A large unorganised market of unlicensed manufacturers, self-styled healers, and outright frauds sells proprietary pills and unlabelled powders, known informally as puriyas, that skip every checkpoint: API compliance, Schedule T GMP mandates, and quality control screening.
What the clinical audit data actually shows
Pharmacovigilance reports and independent laboratory studies from the Indian Council of Medical Research (ICMR), the All India Institute of Medical Sciences (AIIMS), and the Institute of Liver and Biliary Sciences (ILBS) document the scale of the problem:
- Up to 92% of sampled unregulated products showed biological contamination or dangerous botanical substitution
- Close to 50% of sampled products contained undeclared synthetic pharmaceutical agents, or heavy metal levels at toxic, life-threatening concentrations
- The resulting Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI) cases account for a meaningful share of acute liver failure cases in the region, regularly landing patients in critical care or on transplant lists
Synthetic allopathic lacing: the "rapid relief" deception
Genuine Ayurvedic treatment corrects imbalance gradually, over an extended course. To fake a miraculous, instant cure and keep customers returning, unlicensed manufacturers secretly lace herbal products with active pharmaceutical ingredients, exposing patients to massive, unmonitored, unprescribed drug doses.
| Substance laced in | Marketed as | Health consequence |
|---|---|---|
| Corticosteroids (Dexamethasone, Methylprednisolone) | Remedies for asthma, rheumatoid arthritis, joint pain | HPA axis suppression, iatrogenic Cushing's syndrome (weight gain, osteoporosis, hyperglycemia, muscle weakness), a potentially fatal adrenal crisis if the product runs out |
| NSAIDs (Diclofenac) | Herbal analgesics and general pain relievers | Hidden renal toxicity, gastrointestinal ulceration, internal bleeding, worsened cardiovascular conditions |
| PDE5 inhibitors (sildenafil-type compounds), confirmed via LC-MS/MS | Male sexual wellness and vitality products | Serious, unmonitored cardiac risk |
| Benzodiazepines (Clonazepam) | Natural stress relievers, sleep aids, anti-epileptics | Physiological dependence, withdrawal symptoms, DILI, non-cirrhotic portal hypertension (NCPH) |
The Tinospora cordifolia vs Tinospora crispa identification crisis
Botanical substitution poses a separate risk from intentional lacing. Consumption of Tinospora cordifolia (Giloy), promoted widely for immune support, surged during the COVID-19 pandemic. Hepatologists soon reported clusters of patients with severe liver dysfunction resembling autoimmune hepatitis, opening debate on whether genuine Giloy was inducing a new pathology, drug-induced autoimmune hepatitis (DI-AIH).
HPTLC phytochemical fingerprinting paired with DNA barcoding traced the real cause: many affected patients had consumed Tinospora crispa, a climbing shrub in the same genus that looks identical to Tinospora cordifolia but carries strong intrinsic liver toxicity. Even without any synthetic lacing involved, improper identification or unmonitored high-dose use of these botanicals can trigger acute hepatitis with autoimmune features, or unmask latent autoimmune hepatitis in susceptible people, resulting in hepatotoxicity and jaundice. The episode underlines why precise HPTLC botanical authentication needs to happen before manufacturing, to separate a genuine therapeutic species from its toxic look-alike.
How S.P.C. tracking, the Ayush Suraksha portal, and NPvCC close the loop
The National Pharmacovigilance Programme for ASU&H drugs, run by the National Pharmacovigilance Co-ordination Centre (NPvCC) at the All India Institute of Ayurveda (AIIA), forms the surveillance backbone here. Its central tool is the Ayush Suraksha portal, a centralised dashboard where healthcare professionals, hospitals, and consumers submit real-time Adverse Drug Reaction (ADR) reports and flag advertisements promising miraculous, rapid cures.
Rule 158B's S.P.C. codes and Rule 161's QR code traceability supply the enforcement mechanism:
- A physician identifies a case of DILI, HPA axis suppression, or another ADR linked to a product
- The ADR gets reported to the NPvCC through the Ayush Suraksha portal
- Investigators scan the product's S.P.C./QR code, pinging the e-Aushadhi database
- The DVDMS and e-Aushadhi systems trace the batch backwards to its exact Form 25D manufacturing node and batch number
- The State Licensing Authority issues an immediate, targeted digital freeze on that batch across every retail and wholesale point nationwide
- Seized samples undergo LC-MS/MS testing at a central laboratory to confirm the synthetic adulterant or botanical misidentification
- The manufacturer, whose identity sits permanently linked to the S.P.C. and Form 25D license, faces immediate license cancellation and criminal prosecution
Because every legitimate product carries a scannable, verifiable digital code, any item on a shelf without one becomes instantly identifiable as illicit to both consumers and inspectors. This structural reality cuts off the unorganised adulteration economy's access to the market, protecting public health and preserving the credibility of traditional Indian medicine.
Frequently Asked Questions
Below are the most commonly searched questions about the e-Aushadhi portal, the Specific Product Code (S.P.C.), QR code verification, heavy metal limits, and the adulteration risks the 2026 regulatory overhaul was built to eliminate.
What is the e-Aushadhi portal and who is required to register on it?
The e-Aushadhi portal is a mandatory, centralised online supply chain management and licensing platform developed by the Centre for Development of Advanced Computing (C-DAC) for the Ministry of AYUSH. It is designed to digitise and track the entire lifecycle of traditional medicines, from raw material sourcing to the point of retail sale. By law, all entities involved in the commercial production and analysis of Ayurvedic, Siddha, Unani, and Homoeopathy (ASU&H) drugs must register on the portal. This includes in-house manufacturers holding Form 25D licenses, third-party loan licensees operating under Form 25E, and all external public analytical testing laboratories - which must hold relevant ISO 17025 / NABL accreditations - that provide Certificates of Analysis for these products.
What does the S.P.C. code on an Ayurvedic medicine bottle mean?
The Specific Product Code (S.P.C.) is a cryptographic, six-part alphanumeric identifier mandated by Rule 158B under the Ayush Drugs (Eleventh Amendment) Rules, 2026. It denotes the state or Union Territory code, the license type (D for in-house manufacturing or E for third-party loan licensing), the manufacturer's license serial number, the system of medicine (Classical or Patent and Proprietary/PP), the product's specific SKU serial number, and the year of approval. Legally, this uniform code inherently constitutes the manufacturing license number itself, ensuring the physical product is indelibly linked to its approved digital dossier within the e-Aushadhi database and preventing counterfeiting and unauthorised manufacturing.
How do I scan a QR code to verify if my Ayurvedic medicine is authentic?
Consumers, pharmacists, and inspectors can verify authenticity by scanning the QR code, GTIN, or barcode located on the primary or secondary packaging of the medicine using a standard smartphone camera or a designated regulatory mobile application. This scan decodes the embedded URI and executes a secure SSL API query against the C-DAC/DVDMS servers. If the product is compliant and legally registered, the screen instantly reveals eight mandatory data points: the unique S.P.C., the proper and generic name, the brand name, the manufacturer's verified address, the specific batch number, manufacturing and expiry dates (scientifically validated by Rule 161B real-time stability studies), the manufacturing license number, and the complete excipient and ingredient list.
What are the permissible heavy metal limits for Ayurvedic products under the API?
To prevent severe heavy metal toxicity resulting from environmental contamination or the improper calcination of herbo-mineral preparations (Bhasmas), the Ayurvedic Pharmacopoeia of India (API) establishes strict, legally binding maximum permissible limits. Measured in parts per million (ppm), these limits are: Lead (Pb) at 10.0 ppm, Arsenic (As) at 3.0 ppm, Mercury (Hg) at 1.0 ppm, and Cadmium (Cd) at 0.3 ppm. These thresholds are rigorously enforced through mandatory instrumental testing using technologies like Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and Atomic Absorption Spectroscopy (AAS) before a batch can be released for sale into the market.
How does e-Aushadhi prevent synthetic steroid adulteration in herbal remedies?
Historically, unorganised and unlicensed healers adulterated "herbal" powders with potent synthetic allopathic drugs - such as dexamethasone (corticosteroids), diclofenac (NSAIDs), or clonazepam (benzodiazepines) - to manufacture the illusion of rapid symptomatic relief. e-Aushadhi systematically prevents this by enforcing strict Schedule T GMP tracking and mandating that all batches undergo rigorous analytical testing before S.P.C. generation, including LC-MS/MS testing, which definitively detects complex synthetic molecules hidden within herbal matrices1. Furthermore, because every legal product is cryptographically tied to its manufacturer via the S.P.C. code, if a case of steroid-induced Cushing's syndrome or Drug-Induced Liver Injury (DILI) is reported to the NPvCC via the Ayush Suraksha portal, regulators can instantly trace the S.P.C. back to the exact manufacturing node, execute a nationwide batch freeze, and initiate immediate criminal prosecution.
What is the difference between a Form 25D license and a Form 25E loan license?
A Form 25D license is issued to a manufacturer who owns and operates an in-house Ayurvedic, Siddha, Unani, or Homoeopathy production facility, granted after the digital submission of Form 24D through the e-Aushadhi portal1. A Form 25E license, by contrast, is a loan license issued to an applicant who does not own manufacturing infrastructure but legally uses the licensed premises, equipment, and technical staff of an established third-party manufacturer, applied for via Form 25E. Under the modernised regulatory framework, both license types are now granted perpetual validity, removing the historical requirement for periodic renewal - provided the licensee actively maintains Schedule T GMP certification and submits mandatory annual self-compliance declarations through the digital portal.
What are the facility and staffing requirements for an Ayurvedic manufacturing license in India?
To obtain a manufacturing license on e-Aushadhi, an applicant's premises must meet a statutory minimum operational area of 1,200 square feet for a single product category, verified through digitally submitted site layouts and blueprints. Schedule T further mandates dedicated, independent spaces for raw material receipt, manufacturing, quality control, and finished goods storage; herbo-mineral (Rasaushadhi) production, for example, requires a dedicated 150-square-foot raw material store and a properly ventilated furnace or Bhatti section to safely manage toxic fumes from metal calcination. On the staffing side, every application must include the verified, registered details of at least two qualified medical practitioners holding a BAMS (Bachelor of Ayurvedic Medicine and Surgery) or BUMS (Bachelor of Unani Medicine and Surgery) degree along with at least two registered pharmacists, all cross-checked digitally by the portal before approval.
Why do Ayurvedic manufacturers now need a qualified microbiologist on-site?
The 2026 amendments expanded Rule 160B to mandate the continuous presence of a qualified microbiologist at every ASU&H manufacturing site, either a bachelor's degree holder in microbiology with at least six months of verified quality control experience, or a postgraduate degree holder from a recognised university. This requirement exists because Ayurvedic formulations rely heavily on raw, earth-derived botanical materials, which are highly susceptible to microbial contamination, fungal growth, and toxic aflatoxin proliferation if improperly stored or processed. Mandatory on-site microbiological oversight ensures continuous, real-time adherence to the microbial limits defined in the API.
How is the shelf life of an Ayurvedic medicine determined and validated?
Under Rule 161B, shelf-life claims must be backed by rigorous scientific stability data rather than classical textual estimates. Manufacturers seeking rapid market approval can use accelerated stability studies exposing the drug to extreme conditions of roughly 40°C ± 2°C and 75% RH ± 5% RH, but the shelf-life initially granted is capped: a maximum of one year based on a three-month accelerated study, and a maximum of two years based on a six-month study. To retain market authorisation and S.P.C. status beyond this provisional period, the licensee must also complete and submit a full real-time stability study, conducted under standard atmospheric conditions, to the State Licensing Authority within one year of the provisional shelf-life expiring; failing to do so triggers regulatory action and product recall.
Can Ayurvedic manufacturers list all ingredients via QR code instead of printing them on the label?
Yes. Traditional polyherbal formulations often contain dozens of botanical ingredients, mineral excipients (Bhasmas), and detailed contraindications that cannot fit legibly on small physical packaging. The Eleventh Amendment addresses this by inserting sub-rule 161(3A), which formally permits manufacturers to display the complete label information, including the full ingredient and excipient list through a QR code, GTIN, or barcode whenever physical label space is insufficient. This creates a direct, scannable link between the consumer's smartphone and the e-Aushadhi track-and-trace database, resolving packaging constraints while preserving full regulatory transparency.
How does AYUSH QR code traceability compare to Schedule H2 for allopathic medicines?
The AYUSH sector's S.P.C. and QR code framework under Rules 158B and 161 was deliberately aligned with Schedule H2, the traceability mandate the Ministry of Health and Family Welfare introduced for allopathic drugs via Gazette Notification G.S.R. 823(E) in November 2022. Schedule H2 initially covered the top 300 allopathic brands and was expanded in June 2026 to cover vaccines, critical antimicrobials, anti-cancer medications, and NDPS-controlled narcotics and psychotropics, each requiring a QR code that stores nine data elements. Because Indian consumers are increasingly conditioned to scan allopathic medicines for authenticity, the government aligned AYUSH traceability with the same standard so that Ayurvedic, Siddha, Unani, and Homoeopathy products meet an equivalent level of digital accountability and global credibility.
What laboratory tests confirm the safety and authenticity of Ayurvedic medicines?
Third-party laboratories registered on e-Aushadhi rely on four gold-standard instrumental methods to generate the data required for batch release. ICP-MS (Inductively Coupled Plasma Mass Spectrometry) detects trace heavy metals down to parts-per-trillion concentrations and is the definitive test for confirming that Bhasmas have been properly calcined1. AAS (Atomic Absorption Spectroscopy) is a cost-effective, API-mandated standard for routine heavy metal limit testing. HPTLC (High-Performance Thin-Layer Chromatography) generates a visual phytochemical "fingerprint" of a formulation and is the gold standard for confirming the correct botanical species was used1. LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry) is the only technique capable of definitively detecting trace pesticide residues, mycotoxins, and hidden synthetic pharmaceutical adulterants within complex herbal matrices. Results are compiled into a digital Certificate of Analysis (COA) that must be uploaded to e-Aushadhi and linked to the batch number before an S.P.C. QR code can be generated.
How widespread is adulteration in unregulated Ayurvedic and herbal products in India?
Pharmacovigilance and laboratory studies conducted by institutions including ICMR, AIIMS, and the Institute of Liver and Biliary Sciences (ILBS) have found that unregulated, unlicensed traditional medicine products carry a severe contamination burden. Up to 92% of sampled unregulated products exhibited some form of biological contamination or dangerous botanical substitution, and nearly 50% contained undeclared synthetic pharmaceutical agents or toxic levels of heavy metals. This adulteration is a leading contributor to Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI) cases in India, frequently resulting in critical care admission or the need for liver transplantation. e-Aushadhi's mandatory registration, S.P.C. tracking, and analytical testing requirements are designed to systematically shrink this unorganised, unaccountable market.
Why did Giloy (Tinospora cordifolia) cause liver injury cases, and how does e-Aushadhi help prevent this?
During the COVID-19 pandemic, a surge in demand for Tinospora cordifolia (Giloy) for its immunomodulatory properties coincided with clusters of patients developing severe liver dysfunction resembling autoimmune hepatitis. Subsequent investigation using HPTLC phytochemical analysis and DNA barcoding revealed that many of these hepatotoxicity cases were not caused by genuine Tinospora cordifolia at all, but by botanical misidentification: manufacturers and consumers had mistakenly sourced Tinospora crispa, a morphologically identical but intrinsically hepatotoxic lookalike species. This crisis is a central reason the API and e-Aushadhi framework mandate HPTLC fingerprinting before manufacturing, ensuring the correct, therapeutic botanical species is verified, and toxic lookalikes are screened out before a product ever reaches the S.P.C. and QR-code stage.
What was the e-Aushadhi Legacy Module, and what happened to manufacturers who missed the 2026 compliance deadline?
The Legacy Module was a mandatory data-migration mechanism activated by C-DAC on April 28, 2026, following a fresh, cryptographically secure re-registration requirement that began on April 16, 2026. Every existing Form 25D or Form 25E license holder was required to upload their previously approved manual records, formulations, GMP compliance certificates, and past approvals into the module, with State Licensing Authorities verifying this legacy data before any manufacturer could apply for new product approvals, request a WHO-COPP for export, or generate new digital batch records. After May 30, 2026, exclusive use of the e-Aushadhi portal became legally mandatory nationwide, permanently ending offline regulatory approvals, meaning any manufacturer who did not complete this migration lost the ability to obtain new approvals or generate valid S.P.C. codes through any offline channel.
Why is Rule 158B's classification of herbal extracts controversial?
The Ayurvedic Drug Manufacturers' Association (ADMA) has objected to Rule 158B's treatment of all herbal extracts, particularly hydroalcoholic extracts, as Ayurvedic drugs eligible only for an S.P.C. under the Patent and Proprietary (PP) classification. ADMA's argument rests on classical Ayurvedic pharmacology, which determines therapeutic value through rasa, guna, veerya, vipak, and prabhav (RGVV&P) using crude powders, decoctions, or aqueous extracts. The association contends that hydroalcoholic solvent extraction produces a fundamentally different chemical profile from classical preparation methods and constitutes a deviation that should arguably fall outside the strict traditional Ayurveda classification, rather than being folded into the same S.P.C. framework by default.
How does e-Aushadhi detect counterfeit or duplicated QR codes in the supply chain?
The Drugs and Vaccine Distribution Management System (DVDMS) enforces a "digital handshake" protocol at every node of the supply chain from the Form 25D manufacturer's loading dock through district warehouses, wholesale distributors, and retail pharmacies, with each node required to scan the product on both receipt and dispatch. This creates an unbroken digital chain of custody that lets the system detect anomalies automatically. For example, if a specific S.P.C. serial number is scanned at a warehouse in one state days after the identical code was already scanned and dispensed to a patient in another state, the system immediately flags a duplication error. Codes that enter the supply chain without a corresponding origin log from a verified manufacturer are similarly flagged as illegitimate, triggering an automatic transaction block, a digital batch freeze, and an alert to the State Licensing Authority and the regional drug inspectorate.
